AR082022A1 - Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal - Google Patents
Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renalInfo
- Publication number
- AR082022A1 AR082022A1 ARP110102214A ARP110102214A AR082022A1 AR 082022 A1 AR082022 A1 AR 082022A1 AR P110102214 A ARP110102214 A AR P110102214A AR P110102214 A ARP110102214 A AR P110102214A AR 082022 A1 AR082022 A1 AR 082022A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hypertension
- therapeutic agent
- renal dysfunction
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica de liberación sostenida para el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal, que comprende, como ingrediente activo, un compuesto de 2-feniltiazol representado por la fórmula (1), en la cual R1 representa un grupo alcoxi C1-8, un grupo morfolino, un grupo 4-metilpiperazin-1-ilo o un grupo piperidino; R2 representa un grupo nitro o un grupo ciano; X representa un grupo carboxilo o un grupo alcoxicarbonilo C2-7; e Y representa un átomo de hidrógeno o un grupo alquilo C1-6; o una sal farmacéuticamente aceptable de los mismos.Reivindicación 8: La composición farmacéutica de liberación sostenida de acuerdo con cualquiera de las reivindicaciones 1 a 7, en la cual el compuesto de 2-feniltiazol representado por la fórmula (1) es el ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazol carboxílico o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010145056 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082022A1 true AR082022A1 (es) | 2012-11-07 |
Family
ID=45371556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102214A AR082022A1 (es) | 2010-06-25 | 2011-06-24 | Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20130109726A1 (es) |
| EP (1) | EP2586442A4 (es) |
| JP (1) | JPWO2011162390A1 (es) |
| KR (1) | KR20130088755A (es) |
| CN (1) | CN102958521A (es) |
| AR (1) | AR082022A1 (es) |
| AU (1) | AU2011270133B2 (es) |
| BR (1) | BR112012032543A2 (es) |
| CA (1) | CA2803163A1 (es) |
| CL (1) | CL2012003661A1 (es) |
| CO (1) | CO6660504A2 (es) |
| EC (1) | ECSP12012352A (es) |
| MA (1) | MA34328B1 (es) |
| MX (1) | MX2012015040A (es) |
| MY (1) | MY160963A (es) |
| NZ (1) | NZ605516A (es) |
| PE (1) | PE20130241A1 (es) |
| RU (1) | RU2013103366A (es) |
| SG (1) | SG186798A1 (es) |
| TN (1) | TN2012000568A1 (es) |
| TW (1) | TW201215389A (es) |
| UA (1) | UA107716C2 (es) |
| UY (1) | UY33468A (es) |
| WO (1) | WO2011162390A1 (es) |
| ZA (1) | ZA201209388B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2801930A1 (en) | 2010-06-16 | 2011-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
| CN103298466B (zh) | 2010-09-10 | 2015-11-25 | 武田制药美国有限公司 | 茶碱和非布索坦的联合治疗方法 |
| JP5924699B2 (ja) * | 2012-01-27 | 2016-05-25 | 帝人ファーマ株式会社 | 糖尿病の治療薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000051I1 (de) | 1990-11-30 | 2009-02-05 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| US6998404B2 (en) * | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| JP5242393B2 (ja) * | 2005-08-03 | 2013-07-24 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | 高血圧症の治療方法 |
| EP3205337A1 (en) * | 2005-08-18 | 2017-08-16 | Teijin Pharma Limited | Formulation having accurate dose-dividing function |
| EP2101761A4 (en) | 2006-11-13 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS |
| CN101658505A (zh) * | 2009-09-29 | 2010-03-03 | 北京华禧联合科技发展有限公司 | 非布索坦的缓释制剂及其制备方法 |
| CA2801930A1 (en) * | 2010-06-16 | 2011-12-22 | Takeda Pharmaceuticals U.S.A., Inc. | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
-
2011
- 2011-06-24 US US13/806,370 patent/US20130109726A1/en not_active Abandoned
- 2011-06-24 UA UAA201300872A patent/UA107716C2/ru unknown
- 2011-06-24 NZ NZ605516A patent/NZ605516A/en not_active IP Right Cessation
- 2011-06-24 AU AU2011270133A patent/AU2011270133B2/en not_active Ceased
- 2011-06-24 MY MYPI2012701137A patent/MY160963A/en unknown
- 2011-06-24 PE PE2012002449A patent/PE20130241A1/es not_active Application Discontinuation
- 2011-06-24 EP EP11798271.0A patent/EP2586442A4/en not_active Withdrawn
- 2011-06-24 SG SG2012094645A patent/SG186798A1/en unknown
- 2011-06-24 RU RU2013103366/15A patent/RU2013103366A/ru unknown
- 2011-06-24 CA CA2803163A patent/CA2803163A1/en not_active Abandoned
- 2011-06-24 WO PCT/JP2011/064569 patent/WO2011162390A1/ja active Application Filing
- 2011-06-24 UY UY0001033468A patent/UY33468A/es not_active Application Discontinuation
- 2011-06-24 JP JP2012521553A patent/JPWO2011162390A1/ja not_active Ceased
- 2011-06-24 KR KR1020127033036A patent/KR20130088755A/ko not_active Application Discontinuation
- 2011-06-24 TW TW100122222A patent/TW201215389A/zh unknown
- 2011-06-24 AR ARP110102214A patent/AR082022A1/es unknown
- 2011-06-24 MX MX2012015040A patent/MX2012015040A/es not_active Application Discontinuation
- 2011-06-24 MA MA35480A patent/MA34328B1/fr unknown
- 2011-06-24 CN CN2011800311202A patent/CN102958521A/zh active Pending
- 2011-06-24 BR BR112012032543A patent/BR112012032543A2/pt not_active IP Right Cessation
-
2012
- 2012-11-30 TN TNP2012000568A patent/TN2012000568A1/en unknown
- 2012-12-11 ZA ZA2012/09388A patent/ZA201209388B/en unknown
- 2012-12-20 EC ECSP12012352 patent/ECSP12012352A/es unknown
- 2012-12-20 CO CO12230952A patent/CO6660504A2/es unknown
- 2012-12-21 CL CL2012003661A patent/CL2012003661A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102958521A (zh) | 2013-03-06 |
| AU2011270133B2 (en) | 2014-03-20 |
| PE20130241A1 (es) | 2013-03-04 |
| UY33468A (es) | 2012-01-31 |
| CA2803163A1 (en) | 2011-12-29 |
| MA34328B1 (fr) | 2013-06-01 |
| NZ605516A (en) | 2015-02-27 |
| KR20130088755A (ko) | 2013-08-08 |
| WO2011162390A1 (ja) | 2011-12-29 |
| UA107716C2 (ru) | 2015-02-10 |
| MX2012015040A (es) | 2013-02-07 |
| CL2012003661A1 (es) | 2013-04-01 |
| MY160963A (en) | 2017-03-31 |
| JPWO2011162390A1 (ja) | 2013-08-22 |
| RU2013103366A (ru) | 2014-07-27 |
| EP2586442A1 (en) | 2013-05-01 |
| AU2011270133A1 (en) | 2013-01-10 |
| SG186798A1 (en) | 2013-02-28 |
| ZA201209388B (en) | 2013-08-28 |
| EP2586442A4 (en) | 2014-01-01 |
| ECSP12012352A (es) | 2013-02-28 |
| BR112012032543A2 (pt) | 2016-11-22 |
| TW201215389A (en) | 2012-04-16 |
| US20130109726A1 (en) | 2013-05-02 |
| CO6660504A2 (es) | 2013-04-30 |
| TN2012000568A1 (en) | 2014-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| CL2012000001A1 (es) | Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros. | |
| UY33731A (es) | ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep? | |
| CR20110592A (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
| PE20131464A1 (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa | |
| CR20120237A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| AR086652A1 (es) | Metodos de tratamiento, composiciones farmaceuticas y usos de los mismos | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR089812A1 (es) | Agente terapeutico para la diabetes mellitus | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| AR082022A1 (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal | |
| AR088287A1 (es) | Agente terapeutico y agente preventivo para la enfermedad desmielinizante | |
| ES2555785T3 (es) | Remedio o preventivo para esquizofrenia | |
| UY35323A (es) | Derivados sustituidos del ácido bisfenil butanóico como inhibidores de la nep con una mejorada efic acia in vivo | |
| UY33857A (es) | Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos. | |
| AR078424A1 (es) | Derivados de dihidroimidazoquinolina con actividad inhibitoria de tafia, composiciones farmaceuticas que los contienen y su uso como agentes terapeuticos o profilacticos para enfermedades tromboticas | |
| CU20120074A7 (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
| AR082967A1 (es) | Formulaciones de inhibidor de histona desacetilasa en combinacion con bendamustina y uso de las mismas, metodo de tratamiento | |
| UY30939A1 (es) | Nuevos derivados de pirimidina, composiciones farmacéuticas conteniéndolos y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |